<DOC>
	<DOCNO>NCT02965417</DOCNO>
	<brief_summary>This single arm , phase 2 , open-label , multicenter trial patient metastatic colorectal cancer ( mCRC ) acquire resistance anti-epidermal growth factor receptor ( EGFR ) monoclonal antibody ( mAbs ) document mutation extra cellular domain EGFR ( ECD-EGFR ) .</brief_summary>
	<brief_title>Sym004 Metastatic Colorectal Cancer ECD-EGFR Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Exclusion criterion remove due Symphogen 's business decision longer perform clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Resistance anti-EGFR monoclonal antibody</keyword>
	<keyword>Mutation ECD-EGFR</keyword>
</DOC>